{"product_id":"vrtx-business-model-canvas","title":"Vertex Pharmaceuticals Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertex's Business Model: A Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the intricate workings of Vertex Pharmaceuticals’s groundbreaking business model with our comprehensive Business Model Canvas. This in-depth analysis breaks down their core strategies, from innovative R\u0026amp;D to patient access programs, revealing how they consistently deliver life-changing therapies.\u003c\/p\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Vertex Pharmaceuticals's business model. This in-depth Business Model Canvas reveals how the company drives value, captures market share, and stays ahead in a competitive landscape. Ideal for entrepreneurs, consultants, and investors looking for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVertex Pharmaceuticals actively engages in research and development collaborations with leading academic institutions and other biotechnology firms. This strategy is vital for broadening its drug discovery reach and enriching its therapeutic pipeline. \u003c\/p\u003e\n\u003cp\u003eThese partnerships are instrumental in harnessing specialized knowledge and advanced technologies, thereby speeding up the identification of novel disease targets and potential drug compounds. For instance, Vertex has collaborated on cell and genetic therapies, and partnered with companies like CRISPR Therapeutics in the realm of gene-editing advancements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVertex actively collaborates with patient advocacy groups to deeply understand unmet medical needs and the real-world impact of diseases like cystic fibrosis. These partnerships are crucial for gathering direct patient insights, which helps Vertex ensure its research and development efforts are aligned with what matters most to patients. For instance, in 2024, Vertex continued to engage with numerous organizations to refine its patient support services.\u003c\/p\u003e\n\u003cp\u003eThese collaborations also play a significant role in communicating the value of new therapies and establishing essential patient support programs. By working with advocacy groups, Vertex can effectively disseminate information about its treatments and provide resources for patients and their families navigating complex health journeys. This patient-centric approach is a cornerstone of Vertex's strategy, fostering trust and ensuring its innovations address genuine patient priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVertex Pharmaceuticals deeply relies on its partnerships with healthcare providers and institutions. These collaborations are crucial for advancing its pipeline through clinical trials, ensuring patients can access its life-changing therapies once approved, and collecting vital real-world evidence on treatment effectiveness. By the close of 2024, Vertex had established more than 50 Authorized Treatment Centers (ATCs) worldwide specifically for its groundbreaking therapy, CASGEVY, underscoring the importance of these specialized networks for delivering optimal patient care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVertex Pharmaceuticals places significant importance on its relationships with regulatory bodies such as the FDA, EMA, and Health Canada. These partnerships are essential for successfully navigating the rigorous drug approval processes and bringing innovative therapies to patients.  Vertex's commitment to compliance and data integrity is demonstrated by its recent successes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eFDA Approval:\u003c\/strong\u003e Vertex achieved FDA approval for ALYFTREK in December 2024, a key milestone in its drug development pipeline.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEMA and Health Canada Filings:\u003c\/strong\u003e The company also secured approval for JOURNAVX in January 2025, underscoring its ability to meet diverse international regulatory standards.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOngoing Compliance:\u003c\/strong\u003e Maintaining open communication and providing comprehensive data in response to regulatory inquiries are ongoing requirements for Vertex.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVertex Pharmaceuticals relies on strategic alliances with contract manufacturing organizations (CMOs) and specialized distributors. These partnerships are crucial for the efficient production and global distribution of its innovative therapies, ensuring broad patient access.  For instance, Vertex is set to commence manufacturing of CASGEVY at its Portsmouth, NH facility in the latter half of 2025, highlighting its commitment to internal production capabilities alongside external collaborations.\u003c\/p\u003e\n\u003cp\u003eThese collaborations are essential for navigating complex supply chains, particularly for gene therapies like CASGEVY, which require specialized handling and storage. By leveraging the expertise of CMOs, Vertex can scale production effectively to meet anticipated demand. Similarly, partnerships with specialized distributors are vital for reaching patients across diverse geographic markets, ensuring timely and appropriate delivery of treatments.\u003c\/p\u003e\n\u003cp\u003eThe company’s approach to manufacturing and distribution underscores its dedication to patient access and operational excellence.  These key partnerships are fundamental to Vertex's ability to bring its life-changing medicines from development to patients worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliances Drive Biotech Innovation and Patient Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVertex Pharmaceuticals cultivates strategic alliances with academic institutions and other biotech firms to accelerate drug discovery and expand its pipeline. These collaborations, including its significant partnership with CRISPR Therapeutics for gene-editing advancements, are critical for accessing specialized knowledge and cutting-edge technologies, thereby speeding up the identification of novel disease targets and potential drug compounds.\u003c\/p\u003e\n\u003cp\u003eVertex's engagement with patient advocacy groups allows for a deep understanding of unmet medical needs, as demonstrated by its ongoing efforts in 2024 to refine patient support services for conditions like cystic fibrosis. These partnerships are vital for gathering direct patient insights, ensuring research aligns with patient priorities, and effectively communicating the value of new therapies.\u003c\/p\u003e\n\u003cp\u003eCrucial partnerships with healthcare providers and institutions are fundamental to advancing Vertex's pipeline through clinical trials and ensuring patient access to approved therapies. By the end of 2024, Vertex had established over 50 Authorized Treatment Centers globally for CASGEVY, highlighting the importance of these specialized networks for optimal patient care.\u003c\/p\u003e\n\u003cp\u003eVertex's relationships with regulatory bodies, such as the FDA, EMA, and Health Canada, are essential for navigating drug approval processes. Successes like the December 2024 FDA approval for ALYFTREK and the January 2025 approval for JOURNAVX in Europe and Canada underscore Vertex's commitment to compliance and data integrity.\u003c\/p\u003e\n\u003cp\u003eStrategic alliances with contract manufacturing organizations (CMOs) and specialized distributors are vital for the efficient production and global distribution of Vertex's therapies. The planned commencement of CASGEVY manufacturing at its Portsmouth, NH facility in late 2025 exemplifies its approach to scaling production and ensuring broad patient access.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eVertex Pharmaceuticals' business model is centered on developing and commercializing innovative medicines for serious diseases, focusing on a deep understanding of disease biology to create transformative therapies.\u003c\/p\u003e\n\u003cp\u003eThis model emphasizes a strong R\u0026amp;D engine, strategic partnerships, and a patient-centric approach to deliver significant value to patients and stakeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eVertex Pharmaceuticals' Business Model Canvas acts as a pain point reliver by clearly mapping its innovative drug development pipeline and patient-centric approach, addressing the unmet medical needs of individuals suffering from serious diseases.\u003c\/p\u003e\n\u003cp\u003eThis concise, one-page snapshot effectively highlights how Vertex tackles the pain points of chronic and debilitating illnesses through its focused research and development, providing a clear understanding of its value proposition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVertex Pharmaceuticals' core activity revolves around the discovery and development of groundbreaking medicines. Their focus is on tackling diseases with significant unmet medical needs, particularly those with identifiable genetic or biological targets. This dedication drives substantial investment in early-stage research and preclinical studies.\u003c\/p\u003e\n\u003cp\u003eThe company maintains a robust clinical pipeline, extending its efforts beyond its established success in cystic fibrosis into diverse therapeutic areas. This expansion signifies a commitment to addressing a broader spectrum of serious illnesses.\u003c\/p\u003e\n\u003cp\u003eReflecting this commitment, Vertex's research and development expenditures saw a notable increase. In 2024, R\u0026amp;D expenses rose by 15%, reaching $3.63 billion. This substantial investment underscores the company's strategic emphasis on advancing its pipeline and bringing new therapies to patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trials Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVertex Pharmaceuticals' key activity of clinical trials management is paramount for bringing innovative therapies to market. This involves the meticulous design, execution, and oversight of Phase 1, 2, and 3 trials to prove the safety and effectiveness of their drug candidates.\u003c\/p\u003e\n\u003cp\u003eThe company actively recruits patients and manages complex data collection and analysis, all while ensuring strict adherence to global regulatory guidelines. Vertex had a robust pipeline in 2024, with several programs in pivotal development, including those targeting APOL1-mediated kidney disease, IgA nephropathy, and Type 1 diabetes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVertex's manufacturing and supply chain management is crucial for delivering life-changing medicines. This involves meticulously overseeing the entire process, from securing high-quality raw materials to the final packaging and distribution of finished pharmaceutical products. Ensuring the integrity and availability of their treatments globally is paramount.\u003c\/p\u003e\n\u003cp\u003eThe company is actively expanding its manufacturing capabilities. Notably, Vertex anticipates commencing the production of CASGEVY at its facility in Portsmouth, New Hampshire, during the latter half of 2025. This strategic move will bolster their capacity to meet growing patient demand for this innovative therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVertex Pharmaceuticals actively commercializes its approved medicines worldwide, a crucial step for patient access and revenue generation. This involves crafting robust sales strategies, executing targeted marketing campaigns, and managing dedicated sales teams to connect with healthcare providers, payers, and patient advocacy groups.  In 2024, Vertex continued to see significant global success with TRIKAFTA\/KAFTRIO, a testament to its commercialization efforts.\u003c\/p\u003e\n\u003cp\u003eThe company's commitment to expanding patient reach is further demonstrated by the launches of ALYFTREK and JOURNAVX. These new product introductions in 2024 and projected for 2025 are designed to address unmet medical needs and represent key growth drivers for Vertex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Commercialization:\u003c\/strong\u003e Successfully launching and marketing approved medicines across international markets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Force Management:\u003c\/strong\u003e Developing and managing direct sales forces to effectively engage healthcare professionals.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStakeholder Engagement:\u003c\/strong\u003e Building relationships with healthcare providers, payers, and patient organizations to ensure medicine access.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct Launches:\u003c\/strong\u003e Introducing new therapies like ALYFTREK and JOURNAVX to expand the company's portfolio and revenue streams.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVertex Pharmaceuticals actively manages intricate global regulatory environments, a crucial element for bringing its innovative therapies to market. This involves the meticulous preparation and submission of regulatory applications to health authorities worldwide.\u003c\/p\u003e\n\u003cp\u003eEnsuring ongoing adherence to all health authority requirements is a continuous and vital undertaking. This diligent approach guarantees that Vertex's treatments consistently meet the rigorous standards necessary for approval and successful commercialization across diverse geographic regions.\u003c\/p\u003e\n\u003cp\u003eVertex's commitment to regulatory excellence is underscored by recent achievements. In December 2024, the company celebrated a significant milestone with the FDA approval of ALYFTREK. Furthermore, Vertex successfully expanded the label for TRIKAFTA during the same month, demonstrating its ability to navigate and meet evolving regulatory demands.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eNavigating Global Regulatory Landscapes:\u003c\/strong\u003e Vertex engages with numerous health authorities, including the FDA, EMA, and others, to secure approvals for its pipeline and marketed products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Application Preparation and Submission:\u003c\/strong\u003e The company dedicates substantial resources to compiling comprehensive data packages for new drug applications (NDAs) and supplemental new drug applications (sNDAs).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOngoing Compliance:\u003c\/strong\u003e Vertex maintains robust systems for post-market surveillance, pharmacovigilance, and adherence to manufacturing and labeling regulations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey 2024 Milestones:\u003c\/strong\u003e FDA approval of ALYFTREK and label expansion for TRIKAFTA highlight successful navigation of regulatory pathways in the past year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDriving Innovation: From Discovery to Global Patient Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVertex Pharmaceuticals' key activities are centered around innovation and patient access. This includes the rigorous process of drug discovery and development, focusing on serious diseases with limited treatment options. The company also manages extensive clinical trials to prove the safety and efficacy of its therapies.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Vertex is responsible for the manufacturing and global commercialization of its approved medicines. This involves navigating complex regulatory environments to ensure broad patient access to its life-changing treatments. The company's strategic investments in R\u0026amp;D, such as the 15% increase in 2024 to $3.63 billion, directly support these core activities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Activity\u003c\/td\u003e\n\u003ctd\u003eDescription\u003c\/td\u003e\n\u003ctd\u003e2024 Relevance\/Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eDiscovery and development of new medicines\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D expenses increased 15% to $3.63 billion in 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trials Management\u003c\/td\u003e\n\u003ctd\u003eExecuting and overseeing clinical studies\u003c\/td\u003e\n\u003ctd\u003eMultiple pipeline programs in pivotal development (e.g., kidney disease, diabetes).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing \u0026amp; Supply Chain\u003c\/td\u003e\n\u003ctd\u003eProducing and distributing medicines\u003c\/td\u003e\n\u003ctd\u003eExpanding manufacturing capacity, anticipating Portsmouth facility production for CASGEVY in H2 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eMarketing and selling approved therapies\u003c\/td\u003e\n\u003ctd\u003eContinued global success with TRIKAFTA\/KAFTRIO; launches of ALYFTREK and JOURNAVX.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Affairs\u003c\/td\u003e\n\u003ctd\u003eNavigating global health authority requirements\u003c\/td\u003e\n\u003ctd\u003eFDA approval of ALYFTREK (Dec 2024); TRIKAFTA label expansion (Dec 2024).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Vertex Pharmaceuticals Business Model Canvas you are previewing is the exact document you will receive upon purchase. This means you're seeing the complete, professionally structured analysis that will be delivered to you, offering a transparent view of the business strategy. Once your order is complete, you'll gain full access to this identical, ready-to-use document, ensuring no surprises and immediate utility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":55111757922652,"sku":"vrtx-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/vrtx-business-model-canvas.png?v=1753619894","url":"https:\/\/pestel-analysis.com\/products\/vrtx-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}